Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Lymphoid 1CNS 1

Conditions

Neuroblastoma 2Small Cell Lung Carcinoma 1Sarcoma 1Retinoblastoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Medulloblastoma 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Gallbladder Neoplasms 1Familial ependymoma 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Colonic Neoplasms 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Breast Neoplasms, Male 1Breast Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 29Bevacizumab 12Radiotherapy 10Irinotecan 7Carboplatin 7Carmustine 5Magnetic Resonance Spectroscopy 4Filgrastim 4Cyclophosphamide 4Cisplatin 4Vincristine 3Thiotepa 3Surgical Procedures, Operative 3Peripheral Blood Stem Cell Transplantation 3Etoposide 3talampanel 2sargramostim 2antineoplaston AS 2-1 2antineoplaston A10 2abemaciclib 2Topotecan 2Thalidomide 2Tamoxifen 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Procarbazine 2Immunoglobulin G 2Everolimus 2Drug Therapy 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Oligodendroglioma × becatecarin × Clear all
NCT00006102 2013-02-05

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
200 enrolled
CNSLymphoidOther solid neoplasmSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Lymphoma, Medulloblastoma, Neuroblastoma, Oligodendroglioma, Retinoblastoma, Sarcoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Optic Nerve Glioma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡